Grifols
- Market cap
- 5.10B
- P/E (TTM)i
- 10.15
- P/Bi
- 0.82
- EPSi
- 0.66
- Div yieldi
- 3.71%
- 52W posi
- 22%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - General
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Grifols (GRFS) | 5.10B | 10.15 | 0.82 | 3.71% |
| Eli Lilly and Co (LLY) | 1.12T | 39.90 | 33.03 | 0.54% |
| Johnson & Johnson (JNJ) | 622.84B | 29.98 | 7.33 | 2.03% |
| AbbVie (ABBV) | 479.52B | 76.66 | -80.79 | 2.48% |
| Merck & Co (MRK) | 352.29B | 114.23 | 8.40 | 2.35% |
| Novartis AG (NVS) | 272.33B | 21.64 | 6.56 | 3.31% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 32.0% below Morningstar's fair value estimate.
Fair value
Grifols SA earns a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 25% discount to our quantitative fair value estimate of $9.90 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The company's balance sheet bolsters our valuation estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of 2.6 falls in the bottom 30% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.
The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 2.8, for example, sits in the top 10% compared with peers globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. This characteristic further promotes our favorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 08:17:15 · For reference only, not investment advice and not tailored to your situation.